Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
Side-by-side · Research reference

CartalaxvsCortagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED10/32 cited
BAnimal-MechanisticHUMAN-REVIEWED11/35 cited
Cartalax
Bioregulator Peptide · Khavinson School
CartilagePrimary tissuePovorozniuk 2007
MSC → ChondrocyteDifferentiation axisLinkova 2023
BMD ↑Bone density effectPovorozniuk 2007
SQ · Protocol Unspecified
Cortagen
Bioregulatory Tetrapeptide · Khavinson-School
TetrapeptideStructure
↓ LPO productsAntioxidant effectKozina 2007
AnimalEvidence level
Injectable · Animal models

01Mechanism of Action

Parameter
Cartalax
Cortagen
Primary target
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
Cerebral cortex tissue — molecular targets under investigation
Pathway
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007
Downstream effect
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007Anisimov 2004
Feedback intact?
Origin
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004
Antibody development

02Dosage Protocols

Parameter
Cartalax
Cortagen
Animal model dose
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
Human dosing
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
Evidence basis
Animal mechanistic studies only
Animal mechanistic studies
Animal model dose (rat)
Injection protocol (dose not specified in abstracts)
Multiple injections over study period.
Avian model dose (chicken)
40-day injection courseKuznik 2008
Compared to epithalon in hypophysectomized and aged birds.
Human peripheral nerve study
Therapeutic course (protocol details not provided)
Posttraumatic recovery context — reference cited but not detailed.
Route
Injectable (inferred from animal protocols)

03Metabolic / Fat Loss Evidence

Parameter
Cartalax
Cortagen
Fat loss evidence
None — primary target is cartilage and bone tissue, not adipose

04Side Effects & Safety

Parameter
Cartalax
Cortagen
Documented adverse effects
None reported in indexed animal studies
Human safety data
Not available in PubMed-indexed literature
No adverse events reported in peripheral nerve recovery context
Limited detail in available abstracts.
Antioxidant suppression
Suppression of antioxidant activity noted alongside LPO reductionKozina 2007
Mechanism unclear — possible homeostatic adaptation.
Immune/hemostasis effects
No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008
Epithalon reversed deficits; cortagen did not.
Absolute Contraindications
Cartalax
  • ·Unknown due to lack of human clinical trial data
Cortagen
Relative Contraindications
Cartalax
  • ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
Cortagen

05Administration Protocol

Parameter
Cartalax
Cortagen
1. Route
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.
2. Frequency
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.
3. Storage
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.
4. Storage
Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.